What’s Ahead for Antares Pharma, Inc. (ATRS) After Today’s Huge Increase?

February 15, 2018 - By Vivian Currie

Investors sentiment decreased to 1.29 in 2017 Q3. Its down 0.78, from 2.07 in 2017Q2. It turned negative, as 11 investors sold Antares Pharma, Inc. shares while 23 reduced holdings. 18 funds opened positions while 26 raised stakes. 53.56 million shares or 0.15% less from 53.64 million shares in 2017Q2 were reported.
Menta Capital reported 91,482 shares stake. State Street holds 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS) for 2.64 million shares. Tower Ltd Liability Corp (Trc) holds 0% in Antares Pharma, Inc. (NASDAQ:ATRS) or 17,994 shares. Jw Asset Management Llc holds 1.67 million shares. 1.34M were reported by Wells Fargo Mn. Schwab Charles Inv, California-based fund reported 560,936 shares. Fuller Thaler Asset Mgmt has invested 0.03% in Antares Pharma, Inc. (NASDAQ:ATRS). Commercial Bank Of America De reported 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). Two Sigma Securities Ltd Company reported 0% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). The California-based California Employees Retirement System has invested 0% in Antares Pharma, Inc. (NASDAQ:ATRS). Ballentine Prtn Limited Liability Corporation stated it has 0.02% of its portfolio in Antares Pharma, Inc. (NASDAQ:ATRS). 36,900 were accumulated by Alliancebernstein L P. Raymond James Assoc invested in 0% or 11,323 shares. Deutsche Natl Bank Ag owns 739,608 shares or 0% of their US portfolio. Panagora Asset Mngmt has 403,465 shares.

Since October 3, 2017, it had 0 buys, and 2 selling transactions for $1.04 million activity. GARRITY THOMAS J also sold $105,000 worth of Antares Pharma, Inc. (NASDAQ:ATRS) shares.

The stock of Antares Pharma, Inc. (NASDAQ:ATRS) is a huge mover today! The stock increased 14.65% or $0.29 during the last trading session, reaching $2.27. About 5.21 million shares traded or 418.86% up from the average. Antares Pharma, Inc. (NASDAQ:ATRS) has risen 207.14% since February 15, 2017 and is uptrending. It has outperformed by 190.44% the S&P500.
The move comes after 8 months positive chart setup for the $355.65 million company. It was reported on Feb, 15 by Barchart.com. We have $2.34 PT which if reached, will make NASDAQ:ATRS worth $10.67 million more.

Analysts await Antares Pharma, Inc. (NASDAQ:ATRS) to report earnings on March, 13. They expect $-0.03 EPS, 0.00 % or $0.00 from last year’s $-0.03 per share. After $-0.03 actual EPS reported by Antares Pharma, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

Antares Pharma, Inc. (NASDAQ:ATRS) Ratings Coverage

Among 4 analysts covering Antares Pharma (NASDAQ:ATRS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Antares Pharma had 11 analyst reports since March 9, 2016 according to SRatingsIntel. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) has “Buy” rating given on Monday, August 7 by Jefferies. H.C. Wainwright initiated the shares of ATRS in report on Friday, June 23 with “Buy” rating. As per Monday, October 23, the company rating was maintained by H.C. Wainwright. H.C. Wainwright maintained Antares Pharma, Inc. (NASDAQ:ATRS) on Wednesday, November 8 with “Buy” rating. The stock of Antares Pharma, Inc. (NASDAQ:ATRS) earned “Buy” rating by Piper Jaffray on Monday, October 23. The firm has “Buy” rating by Jefferies given on Tuesday, October 10. On Thursday, February 15 the stock rating was maintained by H.C. Wainwright with “Buy”. On Wednesday, March 9 the stock rating was maintained by Jefferies with “Buy”. The firm has “Buy” rating by Piper Jaffray given on Tuesday, July 25. The firm earned “Buy” rating on Friday, September 8 by H.C. Wainwright.

Another recent and important Antares Pharma, Inc. (NASDAQ:ATRS) news was published by Marketwatch.com which published an article titled: “Antares Pharma, Amag Pharma shares soar premarket after FDA approves auto injector” on February 15, 2018.

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company has market cap of $355.65 million. The companyÂ’s injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis and psoriasis patients to self-inject methotrexate at home; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache; ZOMA-Jet and Twin-Jector, a needle-free auto injector to deliver human growth hormone treatment to children without the use of a needle; and VIBEX disposable pressure-assisted auto injectors. It currently has negative earnings. In addition, the firm is developing VIBEX auto injectors for treating anaphylaxis; disposable pen injectors for diabetes and osteoporosis; Makena QuickShot auto injectors for reducing risk of preterm birth; and VIBEX QS Testosterone for testosterone replacement therapy for men who have testosterone deficiency.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.